Researcher Guidance
COVID-19 and IRB Review
Introduction

In this unusual circumstance of pandemic illness, it may be necessary to urgently modify research study procedures. New protocols may also need prioritized IRB review.

Addressed in this Guidance:
- When and how must the Emory IRB be notified of changes to approved research?
- When may prior Emory IRB approval not be needed?
- How quickly can the IRB review new COVID-19 protocols?
- Will Emory IRB’s review capacity be impacted due to Emory’s closures?
- What are my electronic Informed Consent options?
- What if we experience a decrease in the workforce?
- What if I need to request an expanded access use for patient treatment?
- Links to additional resources

Changes to Ongoing Studies

- Changes in IRB-approved research must be submitted to the IRB. Normally, changes may not be implemented before IRB review and approval.

- An exception is when changes are necessary to eliminate apparent immediate hazards to the subject, or the research staff.
  - Complying with Emory’s latest policies halting non-essential research and avoiding in-person contact aligns with this exception.

Eliminating immediate hazards may include:
- actions to reduce potential exposure to COVID-19, or
- to continue to provide medically necessary study care (including study drug) to participants who have been placed in isolation or quarantine, or
- measures to eliminate immediate hazards to research or clinical staff

- When such urgent changes are necessary: Most (not all) must be reported to the IRB as protocol deviations.
  - At Emory, this must be done within 10 business days, as “Reportable New Information” (RNI). Sponsor and FDA notification may also be required.
  - See specific examples in the table below – and a note about external IRBs.
Consent forms: A revised consent form is not required for urgent changes unless the change fundamentally alters what the participants consented to. You can inform participants via other means.

- Consent form process changes should be approved by the IRB (e.g. if adding the option to enroll a subject over the phone or with the use of electronic signature)

- The IRB encourages you to keep careful tracking of all protocol deviations related to the pandemic.

Modifications are required whenever: (a) the changes do not meet the above criteria; (b) there is enough time to obtain IRB approval, or (c) the changes are urgent (thus require a protocol deviation), but also need to be sustained for multiple visits/subjects.

- The Modification can include: a revised version of the protocol, or simply a letter, memo or other document describing temporary changes

External IRB Review: Studies under review by an external IRB must follow the guidelines of that IRB. See the bottom of this webpage for links to major IRB websites. The reviewing IRB’s guidelines may differ.

Contact the analyst or customer service for your IRB of record, and/or see the following webpages for these IRB’s:

- NCI CIRB: https://www.ncicirb.org/announcements/covid-19-and-cirb

Specific examples with IRB requirements (dependent on whether changes must occur before and/or after IRB approval):

<table>
<thead>
<tr>
<th>Modification</th>
<th>Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adding COVID-19 screening before in-person visits</td>
<td>No IRB submission needed if data not used for research purposes</td>
</tr>
<tr>
<td>Using phone or telehealth instead of in-person visits, or doing home visits</td>
<td>RNI and/or Modification – ensure any software is compliant with Emory policy</td>
</tr>
<tr>
<td>Notifying subjects of changes to procedures/visits due to pandemic, via phone or letter (note: if email, must be encrypted)</td>
<td>- No IRB submission needed if communication is limited to scheduling information.</td>
</tr>
<tr>
<td>Event Description</td>
<td>Action/Requirement</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>New enrollment via e-Consent or verbal consent</td>
<td>Modification (may not occur without prior IRB approval) and by using current LITS-approved software. Please, also reference this guidance to know if you need LITS review even if using a new software.</td>
</tr>
<tr>
<td>New enrollment or re-consent via mail or fax, with the same signature method as before</td>
<td>No IRB submission needed (unless other procedures also moving to remote)</td>
</tr>
<tr>
<td>Shipping investigational products directly to research participants</td>
<td>RNI and/or Modification. Consult with IDS for more information about their requirements.</td>
</tr>
<tr>
<td>Temporarily stopping subject recruitment or placing a temporary hold on all or certain study procedures.</td>
<td>Holds or closure to new enrollment: do NOT need to be reported via RNI; just log a comment.</td>
</tr>
<tr>
<td>Temporary holds on all or certain study visits/procedures</td>
<td>RNI only if deviations increase the risk of harm to participants, or adversely affect the integrity of the data; Modification if changes will be sustained and conflict with the current protocol or IRB smartform.</td>
</tr>
<tr>
<td>Other deviations as deemed appropriate to eliminate immediate hazards to subjects due to exposure to COVID-19</td>
<td>RNI only if deviations increase the risk of harm to participants, or adversely affect the integrity of the data; Modification if changes will be sustained and conflict with the current protocol or IRB smartform.</td>
</tr>
</tbody>
</table>

**Ongoing In-Person Visits**

If in-person visits are deemed essential by the Department/Division/School, due to direct benefit to the subject that outweighs the added risk, all possible measures should be taken to maintain as favorable a risk/benefit ratio as possible.

**If Virus Screening Becomes Mandatory:**

If COVID-19 screening becomes mandatory in your clinical area, then that screening would not be considered part of the research procedures, therefore it does not constitute a change in the IRB-approved protocol. **No Modification is required.** If you wish to incorporate the screening data into your research, however, then you would need to submit a protocol modification.

**Review of New Protocols**

The Emory IRB will seek input from faculty and leadership when prioritizing new COVID-19-related protocols. For top priority studies, as in past health emergencies,
we have reviewed and approved new clinical studies within 3 days; minimal risk research can be faster. (*Please use a unique study title, not just “COVID-19 study.”*)

The IRB can help with the entire submission process if urgently needed. We also work with central IRB’s to execute reliance agreements as quickly as possible. (For studies under external IRB review, our local administrative review should not be the limiting factor.) *Please use our protocol templates to avoid delays!!!*

Emory also has a **Rapid Response policy and procedure** that coordinates all relevant ORA units in study startup. The use of this workflow requires high-level approval. To request, please contact Sherry Coleman and Robin Ginn.

**Informed Consent and Study Assessment Documentation**

**Informed Consent:** We have updated our [guidance on electronic informed consent](#) to help with study activities’ planning during this pandemic.

**Reconsent:** Electronic signature, fax, or mail is preferred. If not possible within required timeframe, may do via phone, and send document via encrypted email. Obtain signature at next in-person visit and must submit RNI and/or MOD.

**Real-time assessment of test and safety reports:** The PI or delegated person should still aim to review these documents as promptly as before, especially in these areas:

- Product-related/newly emerging safety issues
- Product problems associated with adverse events

**Remote routing of study documents for review and signature:**

- Email: If documents contain PHI, can use Emory email. Otherwise, **encrypt** and keep replies in same email thread to maintain encryption
- Fax: another preferred method
- Signatures
  - Scanning wet signatures: Acceptable. Also can send photo of signed document. Must be possible to tell that all pages are part of same document/patient record.
  - eSignature options: currently Emory only has RedCap as an option. Another way to do this is via Adobe Acrobat making sure the signature covers the FDA requirements described in [their guidance](#). In general, we recommend using an electronic signature with a date stamp and an keep the email thread (encrypted if non-Emory addresses)
**Reduction in Workforce to Cover Trial Visits/Procedures**

If there is large-scale reduction in on-site workforce, you may not have an IRB-approved, 1572-delegated team member to help with essential study visits and real-time AE assessments. Per FDA guidance, qualified clinicians may cover per the following guidelines without being added to the 1572:

- If possible, the clinician should be CITI and GCP certified.
- Log a comment in eIRB study record before or immediately after this visit takes place to inform IRB.
- If expected to cover multiple times, add person to the study via a MOD.
- Document the coverage in the study records, along with a list of all possible ancillary clinicians.
- Clinician should consult afterward with the PI or a Co-I.

**Reminder:** This is for essential clinical study visits.

**Emergency Use Situations**

If you are faced with the need of treating a patient who is gravely ill due to COVID-19, the FDA has released guidance for single-use treatment with convalescent plasma.

- Consent form: You are still required to obtain informed consent from these subjects. Use our consent document for expanded access use to create your document.
- If this is an emergency, and you do not have time to obtain IRB concurrence, submit a new study submission in eIRB five days after treatment was provided to the patient.
- If you have time to provide the required information for IRB concurrence, submit using a fill out an RNI submission using this guidance.

You should also call the FDA before the use, to obtain their concurrence:

- Highly time-sensitive requests (<4 hours): obtain verbal authorization from FDA’s Office of Emergency Operations (866) 300-4374.
- Not highly time-sensitive requests (4-8 hour response time): complete form 3926 and email to CBER_eIND_Covid-19@FDA.HHS.gov.
**Impact of the University Closure**

The Emory IRB staff are all capable of working remotely. We are also experienced with holding Committee meetings via teleconference. University closure should not significantly impact our ability to review research, including high-priority studies and modifications.

**Additional Questions**

If you have additional questions, please contact our staff leadership at http://irb.emory.edu/about/staff.html

**Links to Guidance and Resources**

- [FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic](#)
- [FDA Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency Guidance for Industry and Health Care Professionals](#)
- [Emory Office of Research Administration COVID-19 Guidance Page](#)
- [Emory University COVID-19 Guidance Page](#)
- [Emory Electronic Informed Consent Guidance](#)
- [Current LITS approved apps and software for PHI or IIHI sharing](#) (review the guidance as some apps only allow sharing between Emory personnel)
- [When is a LITS security review needed?](#) Guidance to help you determine if you need a LITS security review when using a software or app for research.
- [FDA Guidance - Use of Electronic Informed Consent in Clinical Investigations – Questions and Answers](#)
- [FDA Information Sheet - Informed Consent](#)
- [Investigational COVID-19 Convalescent Plasma - Emergency INDs-](#)
- [FDA Guidance: Post-marketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic](#)